Cardiol Therapeutics Inc.

Canada, USA, Germany / Biotechnology
Nasdaq, US; TSX, Canada; FSE, Germany
Bloomberg: CRDL US
ISIN: CA14161Y2006

Pipeline update & FY 2024 results

RATING	**BUY**
PRICE TARGET	**USD 8.50**
Return Potential	755.0%
Risk Rating	High

MAVERIC KICKS OFF, FINAL STRETCH TOWARD FDA APPROVAL IN RP

Cardiol Therapeutics (Cardiol) announced that the first patient has been enrolled in the pivotal MAVERIC phase III study evaluating its oral drug candidate CardiolRx™ for the treatment of recurrent pericarditis (RP), a painful and debilitating heart condition. This is good news as it marks the start of a pivotal phase III trial, an important milestone that brings CardiolRx™ closer to potential FDA approval. The study, led by leading cardiovascular experts and initiated at Northwestern University, is a randomised, double-blind, placebo-controlled trial that will enrol 110 patients at 20 sites in the US, Canada and Europe. The drug addresses a clear unmet need in RP with a promising, non-immunosuppressive oral option. Backed by an orphan drug designation and strong phase II data in RP, we believe the programme has a good chance of success in the phase III trial, and we also see significant commercial potential in this indication. If successful, this study will support submission of a new drug application to the FDA. The next significant catalyst will be the headline results of the multi-national, randomised, placebo-controlled ARCHER phase II study in acute myocarditis (AM), which we expect within the next one to two months. We have updated our SOTP valuation model, which yields an unchanged price target of USD 8.50. We reiterate our Buy recommendation.

First patient enrolled in the pivotal phase III trial called MAVERIC Cardiol has enrolled the first patient in its pivotal phase III MAVERIC trial, evaluating its oral drug CardiolRx™ indicated for RP in patients who are at risk of recurrence following discontinuation of interleukin-1 (IL-1) blocker therapy (i.e. third-line therapy with either ARCALYST/rilonacept or KINERET/anakinra). The trial, which initiated at Northwestern University in Chicago under the direction of Dr Paul Cremer, will be led by additional top international cardiovascular experts from renowned centres, including Dr Allan Klein from the Cleveland Clinic, Dr Massimo Imazio from the University of Udine in Italy, Dr Allen Luis from the Mayo Clinic in Rochester, Dr Antonio Abbate from the University of Virginia and Dr Stephen Nicholls from Monash University in Melbourne, Australia. (p.t.o.)

FINANCIAL HISTORY & PROJECTIONS

	2022	2023	2024	2025E	2026E	2027E
Revenue (CAD m)	0.0	0.0	0.0	0.0	0.0	5.9
Y-o-y growth	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EBIT (CAD m)	-41.3	-29.8	-40.3	-27.0	-24.0	-11.7
EBIT margin	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Net income (CAD m)	-30.9	-28.1	-36.7	-25.8	-23.0	-10.9
EPS (diluted) (CAD)	-0.49	-0.44	-0.51	-0.31	-0.96	-0.12
DPS (CAD)	0.00	0.00	0.00	0.00	0.00	0.00
FCF (CADm)	-27.3	-25.2	-25.1	-22.0	-19.5	-8.2
Net gearing	-113.9%	-123.7%	-123.7%	-218.6%	-149.2%	-1017.6%
Liquid assets (CAD m)	59.5	34.9	30.6	8.5	13.9	5.6

RISKS

Risks include, but are not limited to development, regulatory, competition and financial.

COMPANY PROFILE

Founded in 2017, Cardiol Therapeutics Inc is a Canadian biotech company focused on the research and development of new drugs to treat heart diseases. The lead drug candidate, CardiolRx (cannabidiol) oral solution, is being evaluated in the MAVERIC clinical programme for recurrent pericarditis and the ARCHER clinical programme for acute myocarditis.

MARKET DATA

As of 22 Apr 2025	
Closing Price	USD 0.99
Shares outstanding	82.61m
Market Capitalisation	USD 82.12m
52-week Range	USD 0.81 / 2.97
Avg. Volume (12 Months)	381,671

Multiples	2024	2025E	2026E
P/E	n.a.	n.a.	n.a.
EV/Sales	n.a.	n.a.	n.a.
EV/EBIT	n.a.	n.a.	n.a.
Div. Yield	0.0%	0.0%	0.0%

STOCK OVERVIEW



COMPANY DATA

As of 31 Dec 2024	
Liquid Assets	CAD 30.58m
Current Assets	CAD 31.67m
Intangible Assets	CAD 0.00m
Total Assets	CAD 31.86m
Current Liabilities	CAD 7.01m
Shareholders' Equity	CAD 24.73m

SHAREHOLDERS

Management and Directors	4.7%
Tejara Capital Ltd	3.8%
Advisorshares Investments LLC	1.1%
MMCAP International Inc	1.0%
Freefloat & others	89.4%

Analyst: Christian Orquera, Tel. +49 (0)30 - 80 93 96 90

Focus on MAVERIC phase III trial for prevention of RP, which could potentially enrol very quickly Cardiol recently decided to focus the development strategy for CardiolRx™ in RP on one pivotal phase III RP trial called MAVERIC. MAVERIC is a randomised, double-blind, placebo-controlled phase III study that aims to enrol 110 patients across sites in the US, Canada and Europe, and is designed to demonstrate CardiolRx™'s efficacy in maintaining freedom from recurrence over a 24-week period. The study design was developed in collaboration with Cardiol's top lead investigators and KOLs, and aligned with the FDA in a recent End-of-Phase 2 meeting. Therefore, if successful, this study will support a new drug application for submission to the FDA. Importantly, enrolment for this trial could progress rapidly due to the following reasons:

- Patients who experience a recurrence of pericarditis after discontinuation of IL-1 blockers are in urgent need of an alternative. Immunosuppressants have significant drawbacks, including their high cost (list price of >USD 200k p.a.), high risk of disease recurrence when discontinued, the method of administration (injection), and in particular risk of infection. CardiolRx™ represents a potentially effective, more patient-friendly and cost-effective treatment alternative for these patients with dependence on IL-1 blockers;
- Patients taking immunosuppressive IL-1 blocker treatment are already known to trial sites, and this pool of eligible patients should facilitate fast recruitment. About 20 participating recruitment centres are prepared to start enrolling patients.

In a blue-sky scenario, enrolment could complete in the first half of 2026, with headline results due by mid-2026. A potential approval could take place in H2 2026, which assumes the FDA grants CardiolRx™' an accelerated Fast Track pathway. We conservatively assume a drug approval in 2027.

Given the unmet need, potential for Orphan Drug exclusivity, and the limitations of existing IL-1 blockers, there is a large market opportunity for a differentiated, non-immunosuppressive option in RP such as CardiolRx™ CardiolRx™ is targeting ~38,000 patients (US alone) with recurrent pericarditis. The MAVERIC study is designed to show CardiolRx prevents recurrence in a patient population at high risk for relapse after discontinuation of IL-1 blocker therapy (~75% of patients relapse within 12 weeks of IL-1 blocker discontinuation). The IL-1 blocker RP market is valued at >USD500M in 2025 in the US alone, with the IL-1 blocker ARCALYST currently capturing only ~11% of the 14,000 patients who suffer from multiple recurrences due to the above-mentioned therapy drawbacks. CardiolRx™ is positioned as a more convenient, accessible, non-immunosuppressive oral therapy with disease-modifying potential.

Solid data from phase II pilot RP study underscores the good prospects for success of the phase III study The company has completed a phase II open-label pilot study (MAVERIC-Pilot) in 27 RP patients, which showed compelling clinical results. Patients experienced rapid and sustained reductions in pericarditis pain (mean reduction of 3.7 points from 5.8 at baseline to 2.1) and inflammation, with 93% reporting pain improvement by week 8, and normalisation of C-reactive protein in 80% of those with elevated baseline levels. The study also demonstrated a significant drop in annual recurrence rates, from 5.8 episodes to 0.9 during treatment. CardiolRx™ was well tolerated, and most patients (89%) transitioned successfully into the 18-week extension phase during which CardiolRx™ was administered as a monotherapy. On the strength of these data, we see good chances of success for the phase III pivotal MAVERIC RP study (further details on this trial can be found in the appendix).

CardiolRx™'s multi-national, randomised, double-blind, placebo-controlled ARCHER phase II study in acute myocarditis (AM) is on track to report results within the next one or two months The proof-of-concept ARCHER phase II study is investigating the safety, tolerability and efficacy of CardiolRx™ in 100 AM patients at major cardiac centres in

North America, Europe, and Israel. Cardiol reached its target of enrolling the 100 patients by 24 September 2024. The primary endpoint of the trial will be the assessment of two cardiac magnetic resonance (CMR) imaging measures after 12 weeks of therapy, each of which has been shown to predict the long-term prognosis of patients with acute myocarditis: (1) left ventricular function, which measures myocardial shortening from base to apex, and (2) myocardial edema/fibrosis also known as extra-cellular volume – this is the gold standard and measures scar tissue outside the heart cells following long term inflammation. The goal would be to show a positive change in extra cellular volume, which would be the first ever evidence of anti-fibrotic effect in the heart. We anticipate that the company will report headline results within the next one or two months, and full data will probably be presented at the ESC Congress 2025 from 29 August - 1 September in Madrid.

Figure 1: CardiolRx™ phase II ARCHER acute myocarditis study design



Source: First Berlin Equity Research, Cardiol Therapeutics Inc

Solid phase II ARCHER data could potentially lead to rapid commercialisation of the drug in AM without the need for phase III trials If the data are conclusive, i.e. if this study provides the first clinical evidence of an antifibrotic effect in the heart, we believe the company will not plan a phase III study, but pursue orphan drug status and in combination with the phase II data have the product incorporated into the AM treatment guidelines. The members of the Clinical Steering Committee (CSC) of the ARCHER study are renowned specialists and KOLs who have been involved in the development of international guidelines for the treatment of myocarditis in the past. The treatment guidelines are usually endorsed by the American Heart Association (AHA) and the European Society of Cardiology (ESC). For this route, CardiolRx™ must first be an FDA-approved drug, in this case for the RP indication. We note that other products are currently being recommended off-label under treatment guidelines, such as steroids for RP or AM therapy. This would be a major value inflection point, as it would allow dual use of CardiolRx™ in both RP and AM, potentially simultaneously with RP approval. If the results from ARCHER require additional clinical evidence, we expect the company may out-licence the drug to a pharmaceutical partner who will conduct the phase III trial.

Pre-clinical Heart Failure (HF) Subcutaneous Formulation CRD-38 making progress towards IND. Recent research demonstrates that CRD-38 provides cardioprotection Cardiol announced the publication of research in the Journal of the American College of Cardiology (JACC). The preclinical study, conducted by researchers from Tecnológico de Monterrey and the DeBakey Heart and Vascular Center, highlights the potential of CRD-38 in improving cardiac function and reducing key pathological features such as hypertrophy, remodelling, inflammation, and cell death. The research demonstrates that subcutaneous administration of cannabidiol provides cardioprotection in preclinical models of heart failure. These findings from multiple models indicate that it reduces cardiac fibrosis and preserves

mitochondrial function (which is crucial for heart cell energy production and survival) by enhancing calcium handling in heart cells. Mechanistic studies suggest that this cardioprotective effect is mediated through PPAR-γ activation, which prevents mitochondrial dysfunction and preserves cardiac muscle cell function. These findings provide a deeper understanding of CRD-38's mode of action, how it sustains cardiomyocytes (muscle cells of the heart) and prevents structural deterioration of the heart, reinforcing its potential as a novel treatment for heart failure. They will be incorporated into the company's CRD-38 development programme to complete the IND-enabling work required to progress toward clinical trials.

The preclinical programme CRD-38 is targeting a very attractive market We note that if ARCHER data confirms an anti-fibrotic effect, this HF programme will become particularly compelling, tapping into a multi-billion USD market with broad potential in heart failure with preserved ejection fraction (HFpEF; sometimes also referred to as diastolic heart failure), a major unmet need. CardiolRx™ could become an attractive partnering opportunity for big pharma players targeting cardiovascular diseases.

P&L KPI OVERVIEW OF FY 2024 RESULTS

FY 2024 financial results were broadly in line with our expectations Cardiol reported EBIT of CAD -40.3m (FBe: CAD -39.2m; FY/23: CAD -29.8m), reflecting continued R&D investment and an increase in G&A expenses. Operating expenses rose year-over-year, largely due to a significant increase in general and administrative (G&A) costs, which reached CAD 26.3m (FBe: CAD 27.0m; FY/23: CAD 15.6m). The increase was primarily attributable to higher share-based compensation and the expansion of IR activities following the capital increase in Q4 2024. Research and development expenses came in at CAD 14.0m (FBe: CAD 12.2m; FY/23: CAD 14.2m), remaining relatively flat compared to the previous year. The company advanced its clinical pipeline with significant progress in both the ARCHER and MAVERIC trials. The net financial result amounted to CAD 3.3m (FBe: CAD 1.6m; FY/23: CAD 1.3m), driven by strong interest income and foreign exchange gains. Non-operating income amounted to CAD 0.3m (FBe: CAD -0.9m; FY/23: CAD 0.3m). Consequently, Cardiol recorded a net loss of CAD -36.7m for the year (FBe: CAD -38.5m; FY/23: CAD -28.1m), slightly lower than our forecast.

Table 1: P&L FY 2024 reported figures vs FB estimates and FY 2023 (KPIs)

in CAD'000	2024A	2024E	*Delta*	2023	*Delta*
Revenue	**0**	**0**	-	0	**-**
General & Administrative	26,265	27,000	*-3%*	15,561	*69%*
Research & Development	14,012	12,200	*15%*	14,224	*-1%*
OPEX	40,277	39,200	*3%*	29,786	*35%*
EBIT	**-40,277**	**-39,200**	-	**-29,786**	**-**
Net financial result	3,333	1,600	*108%*	1,326	*151%*
Non-operating income/expenses	266	-900	-	331	*-20%*
Net income	**-36,677**	**-38,500**	-	-28,128	-

Source: First Berlin Equity Research, Cardiol Therapeutics Inc

Revising financial forecasts for 2025 and the following years following development strategy changes Given the change in Cardiol's development strategy for CardiolRx™ for RP to focus on one pivotal phase 3 RP trial instead of two as previously planned, and the delay in the development timeline, we have lowered our R&D/OPEX forecasts for 2025 and subsequent years and pushed back our assumption for a potential approval and launch to 2027 (previously: 2026). The changes to our forecasts are summarised in table 2 overleaf.

Table 2: Changes to our forecasts (KPIs)

Figures in CAD'000	2025E Old	2025E New	2025E *Delta*	2026E Old	2026E New	2026E *Delta*	2027E Old	2027E New	2027E *Delta*
Revenue	0	0	-	4,510	0	*-100%*	114,831	5,905	*-95%*
OPEX	40,000	27,000	*-33%*	40,000	24,000	*-40%*	24,000	17,600	*-27%*
EBIT	-40,000	-27,000	-	-35,490	-24,000	-	90,831	-11,695	-
Net financial result	1,200	1,200	*0%*	1,000	1,000	*0%*	800	800	*0%*
Non-operating income/expenses	0	0	-	0	0	-	0	0	-
Net income	-38,800	-25,800	-	-34,490	-23,000	-	91,631	-10,895	-

Source: First Berlin Equity Research

Balance sheet FY/24 – Cash runway extended into Q3 2026 By the end of FY/24, the cash position declined to CAD 30.6m (FY/23: CAD 34.9m) due to funding of ongoing operations. Company's cash burn was offset by proceeds from the October 2024 capital increase, which raised USD15.5m (CAD ~21.4m) before issuance costs. These funds have extended the cash runway into Q3 2026. Cardiol's equity position dropped from CAD 28.2m at FY/23 to CAD 24.7m at FY/24, reflecting the impact of the annual net loss, partially offset by equity financing and the exercise of performance and restricted share units. The equity ratio (ER) increased slightly to 78% at FY/24 (FY /23 ER: 77%).

FY 2024 cash flow Operating cash outflow was stable at CAD -25.1m (FY/23: CAD -25.2m), despite higher non-cash expenses from share-based compensation (CAD 14.3m vs. CAD 4.2m in FY/23). Financing cash flow reported net proceeds of CAD 18.8m, which will support the company's runway into Q3 2026, as guided.

VALUATION MODEL

Buy rating and price target confirmed We maintain our positive view on Cardiol following the release of FY/24 results, which came in broadly in line with our expectations. Our confidence is underpinned by the continued progress of the clinical pipeline, most notably the positive data from the pilot MAVERIC phase II study in RP and the recently announced enrolment of the first patient for the pivotal MAVERIC phase III trial, as well as the imminent top-line data readout from the multinational ARCHER phase II study in AM expected in the next one to two months. We expect these catalysts to further validate CardiolRx™'s efficacy in inflammatory cardiac conditions and support a significant re-rating of the shares. Following update of our financial forecasts, our SOTP valuation model yields an unchanged price target of USD8.50. We therefore reiterate our Buy rating on Cardiol.

Table 3: "Sum-of-the-parts" valuation model

Compound	Project[1)]	Present Value	Patient Pop (K)	Treatment Cost (USD)	Market Size (USDM)	Market Share (%)	Peak Sales (USDM)	PACME Margin[2)] (%)	Discount Factor (%)	Market Exclusivity[3)] (years)	Time to Market (years)
CardiolRx™	RP-3L - US	USD 179.9M	14K	52,000	728.0M	24%	221.3M	30%	16.0%	7	3
CardiolRx™	RP-3L - EU	USD 92.2M	25K	18,000	450.0M	24%	131.7M	30%	16.0%	7	3
CardiolRx™	RP-2L - US	USD 246.7M	26K	52,000	1,352.0M	24%	390.5M	30%	16.0%	7	5
CardiolRx™	RP-2L - EU	USD 132.9M	47K	18,000	846.0M	24%	257.5M	30%	16.0%	7	5
CardiolRx™	AM - US	USD 134.3M	54K	52,000	2,808.0M	18%	652.1M	20%	16.0%	7	5
CardiolRx™	AM - EU	USD 50.7M	72K	18,000	1,296.0M	18%	322.9M	20%	16.0%	7	5
PACME PV		USD 836.7M			7,480.0M		1,976.0M				
Costs PV[4)]		USD 51.0M									
NPV		USD 785.7M									
Milestones PV		USD 0.0M									
Net cash (proforma)		USD 40.5M									
Fair Value		USD 826.2M									
Share Count (proforma)		97,237K									
Price Target		USD 8.50									
Price Target		EUR 7.50	(based on EUR-USD exchange rate of 1.13)								

1) A project typically refers to a specific indication or, where necessary or relevant, a combination between indication and geographic market

2) PACME (Profit After Costs and Marketing Expenses) reflects the company's profit share on future revenues.
This share may be derived in the form of royalties (outsourced marketing/manufacturing) or operating EBITDA margin (in-house model), or some mix of both (depending on the specific parameters of partnership agreements)

3) Remaining market exclusivity after the point of approval

4) Includes company-level R&D, G&A, Financing Costs and CapEx; COGS and S&M are factored into the PACME margin for each project

APPENDIX

MAVERIC-PILOT RP STUDY – HEADLINE RESULTS

Figure 2: Overview of the phase II MAVERIC-Pilot RP study design



Source: First Berlin Equity Research, Cardiol Therapeutics Inc

The primary endpoint: CardiolRx™ achieved a substantial reduction in pericarditis pain measured with the NRS, which is comparable to rilonacept The patients treated with CardiolRx™ achieved a mean pain reduction of 3.7 points from 5.8 at baseline (range of 4 to 10) to 2.1 (range of 0 to 6) at 8 weeks. Importantly, CardiolRx™'s performance is very similar to that of the immunosuppressive biologic therapy rilonacept (Arcalyst®) in its phase II pilot and phase III trials, which is FDA-approved and is used as a third-line treatment for RP. We give an overview of these results in table 4 below.

Table 4: Patient-reported pericarditis pain: CardiolRx™ versus rilonacept

n=27	Baseline	Week 8	Difference±	rilonacept	Mean Difference±
Mean	5.8	2.1	-3.7	Phase II (n=9)	-3.8 (EoTPδ)
Range	4.0 -10.0	0.0 -6.0		Phase III (n=82)	-3.9 (Week 8)
				Baseline NRS scores for both Phase II and Phase III trials was 4.5	

*numerical rating scale (NRS) is a validated 11-point instrument used to assess patient-reported pericarditis pain. Zero represents "no pain at all" whereas the upper limit of 10 represents "the worst pain ever possible".
± Negative value indicates an improvement in CRP.
δ End of Treatment Period (~Week 6/8)
Rilonacept trial references:
* Klein AL, Lin D, Cremer PC, *et al*. Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial. *Heart.* Published online November 23, 2020. doi:10.1136/heartjnl-2020-317928
* Klein AL, Imazio M, Cremer P, *et al*. Phase 3 trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. *N Engl J Med.* 2021; 384 (1):31-412.doi:10.1056/NEJMoa2027892

Source: First Berlin Equity Research, Cardiol Therapeutics Inc, Allan Klein et al, 2021- phase II & phase III studies

Secondary endpoint of inflammation, as measured by CRP at 8 weeks, also showed positive results CardiolRx™ also led to a normalisation of inflammation, as measured by C-reactive protein (CRP), in 80% of patients who took part in the study whose CRP was elevated at baseline. Importantly, 89% of patients have continued into the 18-week extension phase of the study which demonstrates CardiolRx™ is well-tolerated and that they are satisfied with the pain relief achieved. We give an overview of the CRP results compared to rilonacept (Arcalyst®) in table 5 overleaf.

Table 5: C-reactive protein: CardiolRx™ versus rilonacept

	Baseline	Week 8	Difference*	rilonacept	Mean Difference
Mean	5.71	0.31	-5.39	Phase II	-4.24 (EoTP)
				Phase III (n=82)	-3.48 (Week 6)

Baseline CRP values: Phase II = 4.62; Phase III = 3.7

*Negative value indicates an improvement in CRP.

Rilonacept trial references:

- Klein AL, Lin D, Cremer PC, *et al.* Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial. *Heart.* Published online November 23, 2020. doi:10.1136/heartjnl-2020-317928.
- Klein AL, Imazio M, Cremer P, *et al.* Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. *N Engl J Med*. 2021;384(1):31-41. doi:10.1056/NEJMoa2027892.

Source: First Berlin Equity Research, Cardiol Therapeutics Inc, Allan Klein et al, 2021- phase II & phase III studies

MAVERIC-PHASE III RP STUDY DESIGN

Figure 3: Overview of the MAVERIC phase III RP study design



Source: First Berlin Equity Research, Cardiol Therapeutics Inc

INCOME STATEMENT

All figures in CAD '000	2022	2023	2024	2025E	2026E	2027E
Revenue	**0**	**0**	**0**	**0**	**0**	**5,905**
Cost of goods sold	0	0	0	0	0	0
Gross profit	0	0	0	0	0	5,905
General & Administrative	-22,374	-15,561	-26,265	-12,000	-12,000	-9,600
Research & Development	-18,962	-14,224	-14,012	-15,000	-12,000	-8,000
Total operating expenses (OPEX)	**-41,336**	**-29,786**	**-40,277**	**-27,000**	**-24,000**	**-17,600**
Operating income (EBIT)	**-41,336**	**-29,786**	**-40,277**	**-27,000**	**-24,000**	**-11,695**
Net financial result	4,000	1,326	3,333	1,200	1,000	800
Non-operating income/expenses	6,406	331	266	0	0	0
Pre-tax income (EBT)	**-30,931**	**-28,128**	**-36,677**	**-25,800**	**-23,000**	**-10,895**
Income taxes	0	0	0	0	0	0
Net income / loss	**-30,931**	**-28,128**	**-36,677**	**-25,800**	**-23,000**	**-10,895**
Diluted EPS (CAD)	**-0.49**	**-0.44**	**-0.51**	**-0.31**	**-0.96**	**-0.12**
Ratios						
EBIT Margin on Revenue	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Net Margin on Revenue	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Expenses as % of OPEX						
General & Administrative	54.1%	52.2%	65.2%	44.4%	50.0%	54.5%
Research & Development	45.9%	47.8%	34.8%	55.6%	50.0%	45.5%
Y-Y Growth						
Revenue	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Operating income	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Net income/ loss	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.

BALANCE SHEET

All figures in CAD '000	2022	2023	2024	2025E	2026E	2027E
Assets						
Current Assets, Total	**61,438**	**36,153**	**31,668**	**10,285**	**15,810**	**7,127**
Cash and cash equivalents	59,470	34,932	30,580	8,465	13,890	5,627
Accounts receivables	480	280	362	420	420	0
Inventories	0	0	0	0	0	0
Other current assets	1,488	941	727	1,400	1,500	1,500
Non-Current Assets, Total	**591**	**547**	**196**	**151**	**120**	**101**
Property plant and equipment	296	337	196	151	120	101
Intangible assets	295	210	0	0	0	0
Total Assets	**62,029**	**36,701**	**31,864**	**10,436**	**15,930**	**7,228**
Shareholders' Equity & Debt						
Current Liabilities, Total	**9,805**	**8,295**	**7,010**	**6,453**	**6,518**	**6,585**
Accounts payable	9,334	8,041	6,977	6,419	6,483	6,548
Derivative liabilities	420	238	0	0	0	0
Other current liabilities	50	16	33	34	36	37
Longterm Liabilities, Total	**22**	**159**	**126**	**112**	**101**	**90**
Other liabilities	22	159	126	112	101	90
Shareholders Equity	**52,202**	**28,247**	**24,728**	**3,872**	**9,311**	**553**
Total Consolidated Equity and Debt	**62,029**	**36,701**	**31,864**	**10,436**	**15,930**	**7,228**
Ratios						
Current ratio (x)	6.27	4.36	4.52	1.59	2.43	1.08
Quick ratio (x)	6.27	4.36	4.52	1.59	2.43	1.08
Net gearing	-113.9%	-123.7%	-123.7%	-218.6%	-149.2%	-1017.6%
Book value per share (€)	0.84	0.44	0.35	0.05	0.10	0.01
Net debt	-59,470	-34,932	-30,580	-8,465	-13,890	-5,627
Equity ratio	84.2%	77.0%	77.6%	37.1%	58.4%	7.7%

CASH FLOW STATEMENT

All figures in CAD '000	2022	2023	2024	2025E	2026E	2027E
Net income	**-30,931**	**-28,128**	**-36,677**	**-25,800**	**-23,000**	**-10,895**
Interest, net	-4,000	-1,326	-3,333	-1,200	-1,000	-800
Tax provision	0	0	0	0	0	0
Non-operating items	-6,406	-331	-266	0	0	0
EBIT	**-41,336**	**-29,786**	**-40,277**	**-27,000**	**-24,000**	**-11,695**
Depreciation and amortisation	220	248	373	155	147	140
EBITDA	**-41,116**	**-29,537**	**-39,904**	**-26,845**	**-23,853**	**-11,556**
Derivative liability	-6,241	-182	-238	0	0	0
Share & w arrant based payments	6,894	4,173	14,277	4,000	2,500	2,200
Changes in w orking capital	5,748	-546	-932	-1,289	-34	486
Cash interest net	4,000	1,326	3,333	1,200	1,000	800
Other adjustments	3,495	-415	-1,598	1,000	1,000	0
Operating cash flow	**-27,220**	**-25,180**	**-25,061**	**-21,934**	**-19,388**	**-8,070**
CapEx	-75	-64	-21	-110	-116	-121
Free cash flow	**-27,295**	**-25,245**	**-25,082**	**-22,044**	**-19,503**	**-8,191**
Other investments	0	0	0	0	0	0
Cash flow from investing	**-75**	**-64**	**-21**	**-110**	**-116**	**-121**
Debt Financing, net	0	0	0	0	0	0
Equity Financing, net	0	0	18,882	0	25,000	0
Other financiing activities	-54	-55	-42	-71	-72	-73
Cash flow from financing	**-54**	**-55**	**18,840**	**-71**	**24,928**	**-73**
Net cash flows	**-27,349**	**-25,300**	**-6,242**	**-22,115**	**5,425**	**-8,264**
Cash, start of the year	83,899	59,470	34,932	30,580	8,465	13,890
Impact of exchange rates on cash	2,920	762	1,890	0	0	0
Cash, end of the year	**59,470**	**34,932**	**30,580**	**8,465**	**13,890**	**5,627**
Y-Y Growth						
Operating Cashflow	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Free cashflow	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.

Imprint / Disclaimer

First Berlin Equity Research

First Berlin Equity Research GmbH ist ein von der BaFin betreffend die Einhaltung der Pflichten des §85 Abs. 1 S. 1 WpHG, des Art. 20 Abs. 1 Marktmissbrauchsverordnung (MAR) und der Markets Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Durchführungsverordnung und der Markets in Financial Instruments Regulations (MiFIR) beaufsichtigtes Unternehmen.

First Berlin Equity Research GmbH is one of the companies monitored by BaFin with regard to its compliance with the requirements of Section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) Market Abuse Regulation (MAR) and Markets in Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Commission Delegated Regulation and Markets in Financial Instruments Regulations (MiFIR).

Anschrift:
First Berlin Equity Research GmbH
Friedrichstr. 34
10117 Berlin
Germany

Vertreten durch den Geschäftsführer: Martin Bailey

Telefon: +49 (0) 30-80 93 9 680
Fax: +49 (0) 30-80 93 9 687
E-Mail: info@firstberlin.com

Amtsgericht Berlin Charlottenburg HR B 103329 B
UST-Id.: 251601797
Ggf. Inhaltlich Verantwortlicher gem. § 6 MDStV
First Berlin Equity Research GmbH

Authored by: Christian Orquera, Analyst
All publications of the last 12 months were authored by Christian Orquera.

Company responsible for preparation: First Berlin Equity Research GmbH, Friedrichstraße 69, 10117 Berlin

The production of this recommendation was completed on 23 April 2025 at 14:46

Person responsible for forwarding or distributing this financial analysis: Martin Bailey

INFORMATION PURSUANT TO SECTION 85 (1) SENTENCE 1 OF THE GERMAN SECURITIES TRADING ACT [WPHG], TO ART. 20 (1) OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF APRIL 16, 2014, ON MARKET ABUSE (MARKET ABUSE REGULATION) AND TO ART. 37 OF COMMISSION DELEGATED REGULATION (EU) NO 2017/565 (MIFID) II.

First Berlin Equity Research GmbH (hereinafter referred to as: “First Berlin”) prepares financial analyses while taking the relevant regulatory provisions, in particular section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) and art. 37 of Commission Delegated Regulation (EU) no. 2017/565 (MiFID II) into consideration. In the following First Berlin provides investors with information about the statutory provisions that are to be observed in the preparation of financial analyses.

CONFLICTS OF INTEREST

In accordance with art. 37 (1) of Commission Delegated Regulation (EU) no. 2017/565 (MiFID) II and art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) investment firms which produce, or arrange for the production of, investment research that is intended or likely to be subsequently disseminated to clients of the firm or to the public, under their own responsibility or that of a member of their group, shall ensure the implementation of all the measures set forth in accordance with Article 34 (2) lit. (b) of Regulation (EU) 2017/565 in relation to the financial analysts involved in the production of the investment research and other relevant persons whose responsibilities or business interests may conflict with the interests of the persons to whom the investment research is disseminated. In accordance with art. 34 (3) of Regulation (EU) 2017/565 the procedures and measures referred to in paragraph 2 lit. (b) of such article shall be designed to ensure that relevant persons engaged in different business activities involving a conflict of interests carry on those activities at a level of independence appropriate to the size and activities of the investment firm and of the group to which it belongs, and to the risk of damage to the interests of clients.

In addition, First Berlin shall pursuant to Article 5 of the Commission Delegated Regulation (EU) 2016/958 disclose in their recommendations all relationships and circumstances that may reasonably be expected to impair the objectivity of the financial analyses, including interests or conflicts of interest, on their part or on the part of any natural or legal person working for them under a contract, including a contract of employment, or otherwise, who was involved in producing financial analyses, concerning any financial instrument or the issuer to which the recommendation directly or indirectly relates.

With regard to the financial analyses of Cardiol Therapeutics Inc. the following relationships and circumstances exist which may reasonably be expected to impair the objectivity of the financial analyses: The author, First Berlin, or a company associated with First Berlin reached an agreement with the Cardiol Therapeutics Inc. for preparation of a financial analysis for which remuneration is owed.

Furthermore, First Berlin offers a range of services that go beyond the preparation of financial analyses. Although First Berlin strives to avoid conflicts of interest wherever possible, First Berlin may maintain the following relations with the analysed company, which in particular may constitute a potential conflict of interest:

- The author, First Berlin, or a company associated with First Berlin owns a net long or short position exceeding the threshold of 0.5 % of the total issued share capital of the analysed company;
- The author, First Berlin, or a company associated with First Berlin holds an interest of more than five percent in the share capital of the analysed company;

- The author, First Berlin, or a company associated with First Berlin provided investment banking or consulting services for the analysed company within the past twelve months for which remuneration was or was to be paid;
- The author, First Berlin, or a company associated with First Berlin reached an agreement with the analysed company for preparation of a financial analysis for which remuneration is owed;
- The author, First Berlin, or a company associated with First Berlin has other significant financial interests in the analysed company;

With regard to the financial analyses of Cardiol Therapeutics Inc. the following of the aforementioned potential conflicts of interests or the potential conflicts of interest mentioned in Article 6 paragraph 1 of the Commission Delegated Regulation (EU) 2016/958 exist: The author, First Berlin, or a company associated with First Berlin reached an agreement with the Cardiol Therapeutics Inc. for preparation of a financial analysis for which remuneration is owed.

In order to avoid and, if necessary, manage possible conflicts of interest both the author of the financial analysis and First Berlin shall be obliged to neither hold nor in any way trade the securities of the company analyzed. The remuneration of the author of the financial analysis stands in no direct or indirect connection with the recommendations or opinions represented in the financial analysis. Furthermore, the remuneration of the author of the financial analysis is neither coupled directly to financial transactions nor to stock exchange trading volume or asset management fees.

INFORMATION PURSUANT TO SECTION 64 OF THE GERMAN SECURITIES TRADING ACT [WPHG], DIRECTIVE 2014/65/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 15 MAY 2014 ON MARKETS IN FINANCIAL INSTRUMENTS AND AMENDING DIRECTIVE 2002/92/EC AND DIRECTIVE 2011/61/EU, ACCOMPANIED BY THE MARKETS IN FINANCIAL INSTRUMENTS REGULATION (MIFIR, REG. EU NO. 600/2014).

First Berlin notes that is has concluded a contract with the issuer to prepare financial analyses and is paid for that by the issuer. First Berlin makes the financial analysis simultaneously available for all interested security financial services companies. First Berlin thus believes that it fulfils the requirements of section 64 WpHG for minor non-monetary benefits.

PRICE TARGET DATES

Unless otherwise indicated, current prices refer to the closing prices of the previous trading day.

AGREEMENT WITH THE ANALYSED COMPANY AND MAINTENANCE OF OBJECTIVITY

The present financial analysis is based on the author's own knowledge and research. The author prepared this study without any direct or indirect influence exerted on the part of the analysed company. Parts of the financial analysis were possibly provided to the analysed company prior to publication in order to avoid inaccuracies in the representation of facts. However, no substantial changes were made at the request of the analysed company following any such provision.

ASSET VALUATION SYSTEM

First Berlin's system for asset valuation is divided into an asset recommendation and a risk assessment.

ASSET RECOMMENDATION

The recommendations determined in accordance with the share price trend anticipated by First Berlin in the respectively indicated investment period are as follows:

Category		1	2
Current market capitalisation (in €)		0 - 2 billion	> 2 billion
Strong Buy[1]	An expected favourable price trend of:	> 50%	> 30%
Buy	An expected favourable price trend of:	> 25%	> 15%
Add	An expected favourable price trend of:	0% to 25%	0% to 15%
Reduce	An expected negative price trend of:	0% to -15%	0% to -10%
Sell	An expected negative price trend of:	< -15%	< -10%

[1] The expected price trend is in combination with sizable confidence in the quality and forecast security of management.

Our recommendation system places each company into one of two market capitalisation categories. Category 1 companies have a market capitalisation of €0 – €2 billion, and Category 2 companies have a market capitalisation of > €2 billion. The expected return thresholds underlying our recommendation system are lower for Category 2 companies than for Category 1 companies. This reflects the generally lower level of risk associated with higher market capitalisation companies.

RISK ASSESSMENT

The First Berlin categories for risk assessment are low, average, high and speculative. They are determined by ten factors: Corporate governance, quality of earnings, management strength, balance sheet and financial risk, competitive position, standard of financial disclosure, regulatory and political uncertainty, strength of brandname, market capitalisation and free float. These risk factors are incorporated into the First Berlin valuation models and are thus included in the target prices. First Berlin customers may request the models.

RECOMMENDATION & PRICE TARGET HISTORY

Report No.:	Date of publication	Previous day closing price	Recommendation	Price target
Initial Report	11 April 2023	USD0.51	Buy	USD3.60
2	24 May 2023	USD0.68	Buy	USD3.60
3	30 August 2023	USD0.98	Buy	USD3.60
4	19 January 2024	USD1.06	Buy	USD3.60
5	27 February 2024	USD1.76	Buy	USD3.60
6	14 June 2024	USD2.36	Buy	USD8.50
7	28 October 2024	USD1.92	Buy	USD8.50
8	Today	USD0.99	Buy	USD8.50

INVESTMENT HORIZON

Unless otherwise stated in the financial analysis, the ratings refer to an investment period of twelve months.

UPDATES

At the time of publication of this financial analysis it is not certain whether, when and on what occasion an update will be provided. In general First Berlin strives to review the financial analysis for its topicality and, if required, to update it in a very timely manner in connection with the reporting obligations of the analysed company or on the occasion of ad hoc notifications.

SUBJECT TO CHANGE

The opinions contained in the financial analysis reflect the assessment of the author on the day of publication of the financial analysis. The author of the financial analysis reserves the right to change such opinion without prior notification.

Legally required information regarding

- **key sources of information in the preparation of this research report**
- **valuation methods and principles**
- **sensitivity of valuation parameters**

can be accessed through the following internet link: https://firstberlin.com/disclaimer-english-link/

SUPERVISORY AUTHORITY: Bundesanstalt für Finanzdienstleistungsaufsicht (German Federal Financial Supervisory Authority) [BaFin], Graurheindorferstraße 108, 53117 Bonn and Marie-Curie-Straße 24-28, 60439 Frankfurt am Main

EXCLUSION OF LIABILITY (DISCLAIMER)

RELIABILITY OF INFORMATION AND SOURCES OF INFORMATION

The information contained in this study is based on sources considered by the author to be reliable. Comprehensive verification of the accuracy and completeness of information and the reliability of sources of information has neither been carried out by the author nor by First Berlin. As a result no warranty of any kind whatsoever shall be assumed for the accuracy and completeness of information and the reliability of sources of information, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the accuracy and completeness of information and the reliability of sources of information.

RELIABILITY OF ESTIMATES AND FORECASTS

The author of the financial analysis made estimates and forecasts to the best of the author's knowledge. These estimates and forecasts reflect the author's personal opinion and judgement. The premises for estimates and forecasts as well as the author's perspective on such premises are subject to constant change. Expectations with regard to the future performance of a financial instrument are the result of a measurement at a single point in time and may change at any time. The result of a financial analysis always describes only one possible future development – the one that is most probable from the perspective of the author – of a number of possible future developments.

Any and all market values or target prices indicated for the company analysed in this financial analysis may not be achieved due to various risk factors, including but not limited to market volatility, sector volatility, the actions of the analysed company, economic climate, failure to achieve earnings and/or sales forecasts, unavailability of complete and precise information and/or a subsequently occurring event which affects the underlying assumptions of the author and/or other sources on which the author relies in this document. Past performance is not an indicator of future results; past values cannot be carried over into the future.

Consequently, no warranty of any kind whatsoever shall be assumed for the accuracy of estimates and forecasts, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the correctness of estimates and forecasts.

INFORMATION PURPOSES, NO RECOMMENDATION, SOLICITATION, NO OFFER FOR THE PURCHASE OF SECURITIES

The present financial analysis serves information purposes. It is intended to support institutional investors in making their own investment decisions; however in no way provide the investor with investment advice. Neither the author, nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be considered to be acting as an investment advisor or portfolio manager vis-à-vis an investor. Each investor must form his own independent opinion with regard to the suitability of an investment in view of his own investment objectives, experience, tax situation, financial position and other circumstances.

The financial analysis does not represent a recommendation or solicitation and is not an offer for the purchase of the security specified in this financial analysis. Consequently, neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall as a result be liable for losses incurred through direct or indirect employment or use of any kind whatsoever of information or statements arising out of this financial analysis.

A decision concerning an investment in securities should take place on the basis of independent investment analyses and procedures as well as other studies including, but not limited to, information memoranda, sales or issuing prospectuses and not on the basis of this document.

NO ESTABLISHMENT OF CONTRACTUAL OBLIGATIONS

By taking note of this financial analysis the recipient neither becomes a customer of First Berlin, nor does First Berlin incur any contractual, quasi-contractual or pre-contractual obligations and/or responsibilities toward the recipient. In particular no information contract shall be established between First Berlin and the recipient of this information.

NO OBLIGATION TO UPDATE

First Berlin, the author and/or the person responsible for passing on or distributing the financial analysis shall not be obliged to update the financial analysis. Investors must keep themselves informed about the current course of business and any changes in the current course of business of the analysed company.

DUPLICATION

Dispatch or duplication of this document is not permitted without the prior written consent of First Berlin.

SEVERABILITY

Should any provision of this disclaimer prove to be illegal, invalid or unenforceable under the respectively applicable law, then such provision shall be treated as if it were not an integral component of this disclaimer; in no way shall it affect the legality, validity or enforceability of the remaining provisions.

APPLICABLE LAW, PLACE OF JURISDICTION

The preparation of this financial analysis shall be subject to the law obtaining in the Federal Republic of Germany. The place of jurisdiction for any disputes shall be Berlin (Germany).

NOTICE OF DISCLAIMER

By taking note of this financial analysis the recipient confirms the binding nature of the above explanations.

By using this document or relying on it in any manner whatsoever the recipient accepts the above restrictions as binding for the recipient.

QUALIFIED INSTITUTIONAL INVESTORS

First Berlin financial analyses are intended exclusively for qualified institutional investors.

This report is not intended for distribution in the USA and/or Canada.